The debate highlighted broad cellular toxicity of existing HSP inhibitors but did not resolve how to engineer selectivity for tau-associated chaperones. This structure-activity relationship gap prevents rational drug design. Source: Debate session sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd (Analysis: SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd)
Landscape Summary: What are the minimal structural requirements for HSP70/HSP90 inhibitors to achieve tau-selectivity over essential cellular functions? is a 0.85 priority gap in drug-discovery. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
What are the minimal structural requirements for HSP70/HSP90 inhibitors to achieve tau-selectivity over essential cellular functions? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: